Literature DB >> 19901860

Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007.

Lillian B Brown1, Robert Krysiak, Gift Kamanga, Clemente Mapanje, Happiness Kanyamula, Blessings Banda, Chisale Mhango, Mariah Hoffman, Debbie Kamwendo, Marcia Hobbs, Mina C Hosseinipour, Francis Martinson, Myron S Cohen, Irving F Hoffman.   

Abstract

BACKGROUND: Malawi adopted syndromic management of sexually transmitted infections in 1993. Based on clinical efficacy and cost, gentamicin 240 mg intramuscularly, and doxycycline 100 mg twice daily x 7 days was selected as the first line regimen to treat urethritis. We sought to establish current laboratory-based Neisseria gonorrhoeae antibiotic susceptibility patterns for Malawi and describe the pattern of susceptibility since syndromic management began.
METHODS: Between May 15 and August 10, 2007, 126 men with urethritis attending the STD clinic at Kamuzu Central Hospital in Lilongwe had history, genital exam, and urethral swabs taken. All were treated with gentamicin and doxycycline in accordance with Malawi guidelines. Gonorrhea was diagnosed by Gram stain and culture. Antimicrobial susceptibility patterns in gonococcal isolates were determined by disk diffusion and E-test minimum inhibitory concentration (MIC) determination and agar dilution MIC determination.
RESULTS: One hundred six isolates were cultured, and MICs were determined for 100. High levels of resistance to tetracycline and penicillin were observed, but isolates were uniformly susceptible to both gentamicin and ciprofloxacin. Susceptibility patterns identified by the agar dilution MIC and E-test MIC agreed.
CONCLUSIONS: The most recent study continues the trend of high susceptibility of gonococcal isolates to gentamicin in Malawi after 14 years of use and suggests agar dilution MICs may be substituted with the simpler E-test methods in future susceptibility testing. However because of the lack of susceptibility criteria for aminoglycosides for N. gonorrhoeae and the difficulty obtaining clinical/in vitro correlates in this setting, caution should be exercised in using these data for modifying treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19901860     DOI: 10.1097/OLQ.0b013e3181bf575c

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  37 in total

Review 1.  Preparing for an era of untreatable gonorrhea.

Authors:  Lindley A Barbee
Journal:  Curr Opin Infect Dis       Date:  2014-06       Impact factor: 4.915

Review 2.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Gentamicin Susceptibility among a Sample of Multidrug-Resistant Neisseria gonorrhoeae Isolates in India.

Authors:  Manju Bala; Vikram Singh; Aradhana Bhargava; Monika Kakran; Naveen Chandra Joshi; Ravi Bhatnagar
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 4.  Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.

Authors:  Magnus Unemo; Robert A Nicholas
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

5.  Gonococcal resistance: are cephalosporins next?

Authors:  Robert D Kirkcaldy; Ronald C Ballard; Deborah Dowell
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

6.  Susceptibility of Neisseria gonorrhoeae to Gentamicin-Gonococcal Isolate Surveillance Project, 2015-2016.

Authors:  Laura M Mann; Robert D Kirkcaldy; John R Papp; Elizabeth A Torrone
Journal:  Sex Transm Dis       Date:  2018-02       Impact factor: 2.830

7.  Determination of In Vitro Activities of Solithromycin at Different pHs and Its Intracellular Activity against Clinical Isolates of Neisseria gonorrhoeae from a Laboratory Collection.

Authors:  Julia Mallegol; Prabhavathi Fernandes; Christine Seah; Cyril Guyard; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

8.  In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae.

Authors:  Lindley A Barbee; Olusegun O Soge; King K Holmes; Matthew R Golden
Journal:  J Antimicrob Chemother       Date:  2014-01-26       Impact factor: 5.790

9.  The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.

Authors:  Robert D Kirkcaldy; Hillard S Weinstock; Page C Moore; Susan S Philip; Harold C Wiesenfeld; John R Papp; Peter R Kerndt; Shacondra Johnson; Khalil G Ghanem; Edward W Hook
Journal:  Clin Infect Dis       Date:  2014-07-16       Impact factor: 9.079

Review 10.  Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century.

Authors:  Magnus Unemo; Carlos Del Rio; William M Shafer
Journal:  Microbiol Spectr       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.